for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Minerva Neurosciences Inc

NERV.OQ

Latest Trade

8.63USD

Change

-0.03(-0.35%)

Volume

152,093

Today's Range

8.44

 - 

8.82

52 Week Range

4.10

 - 

12.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.66
Open
8.66
Volume
152,093
3M AVG Volume
16.93
Today's High
8.82
Today's Low
8.44
52 Week High
12.95
52 Week Low
4.10
Shares Out (MIL)
39.03
Market Cap (MIL)
337.96
Forward P/E
-5.90
Dividend (Yield %)
--

Latest Developments

More

Minerva Neurosciences Reports Quarterly Loss Per Share $0.32

Minerva Neurosciences Q2 Loss Per Share $0.32

Minerva Neurosciences Q2 Loss Per Share $0.32

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Minerva Neurosciences Inc

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Industry

Biotechnology & Drugs

Contact Info

1601 Trapelo Rd Ste 286

+1.617.6007373

http://minervaneurosciences.com/

Executive Leadership

Remy Luthringer

Executive Chairman of the Board, Chief Executive Officer

Richard E. Russell

President

Geoffrey Race

Executive Vice President, Chief Financial Officer and Chief Business Officer

Joseph Reilly

Chief Operating Officer, Senior Vice President

Frederick Ahlholm

Senior Vice President, Chief Accounting Officer

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.990

2017

-1.080

2018

-1.290

2019(E)

-1.426
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.02
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-39.85
Return on Equity (TTM)
-38.07

Latest News

BRIEF-Minerva Neurosciences Q1 Loss Per Share $0.32

* MINERVA NEUROSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATES

BRIEF-Minerva Neurosciences Reports Q1 Loss Per Share $0.32

* MINERVA NEUROSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATES

BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 2B TRIAL OF MIN 117 TO TREAT MAJOR DEPRESSIVE DISORDER

BRIEF-Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter And Year End Financial Results

* MINERVA NEUROSCIENCES REPORTS FISCAL 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS AND BUSINESS UPDATES

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR

BRIEF-Minerva Neurosciences Screens First Patient In Phase 3 Trial Of MIN-101 To Treat Negative Symptoms In Schizophrenia

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

BRIEF-Minerva Neurosciences Screens First Patient In Phase 3 Trial Of Schizophrenia Drug

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Source text for Eikon: Further company coverage:

BRIEF-Minerva Neurosciences names Richard Russell president

* MINERVA NEUROSCIENCES INC - REMY LUTHRINGER WILL CONTINUE AS CHIEF EXECUTIVE OFFICER OF MINERVA WHILE RESIGNING HIS POSITION AS PRESIDENT Source text for Eikon: Further company coverage:

BRIEF-Minerva Neurosciences reports Q3 loss per share $0.28

* Minerva Neurosciences Inc reports third quarter 2017 financial results and business updates

BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant

* Minerva Neurosciences announces enrollment of first patient in phase 2b trial of seltorexant (min-202) as adjunctive therapy in patients with major depressive disorder

BRIEF-Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant

* Minerva Neurosciences announces enrollment of first patient in phase 2B trial of Seltorexant (MIN-202) as adjunctive therapy in patients with major depressive disorder

BRIEF-Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen

* Minerva Neurosciences announces European Commission approval of amendment of MIN-202 agreement with Janssen

BRIEF-Minerva Neurosciences Q2 loss per share $0.27

* Minerva Neurosciences reports second quarter 2017 financial results and business updates

BRIEF-American Journal of Psychiatry publishes Minerva Neurosciences' MIN-101 Phase 2b trial results

* American Journal of Psychiatry publishes Minerva Neurosciences' MIN-101 Phase 2b trial results for treatment of negative symptoms in Schizophrenia

BRIEF-Minerva Neurosciences announces departure of directors

* Announced resignation of two members of its board of directors, Michele Ollier and Nico Vandervelpen

BRIEF-Minerva Neurosciences announces departure of directors

* Minerva Neurosciences announces departure of directors Source text for Eikon: Further company coverage:

BRIEF-Minerva Neurosciences prices 5 mln common shares at $7.75 per share

* Minerva neurosciences announces pricing of public offering of common stock

BRIEF-Minerva announces completion of bridging study to select improved formulation of MIN-101 for use in phase 3 trial for the treatment of negative symptoms in patients with schizophrenia

* Minerva announces completion of bridging study to select improved formulation of MIN-101 for use in phase 3 trial for the treatment of negative symptoms in patients with schizophrenia

BRIEF-Minerva Neurosciences enters amendment to co-development and license agreement with Janssen Pharmaceutica NV

* Minerva Neurosciences - on June 13, co entered amendment to co-development and license agreement between company and Janssen Pharmaceutica NV

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up